RxDoctor Payments Data

Neil Khurana, MD

Family Medicine · Weirton, WVNPI 1801383369

Payments from drug & device makers

$4,521in general payments, 2019–2025

Across 160 payments — averaging $28.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$654
  • AbbVie$482
  • Medtronic$431
  • Inari Medical, Inc.$389
  • Stryker$385
  • Bard Peripheral Vascular, Inc.$233
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$4,521100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,521 in reported general payments places this provider in the 85th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$100,641
Medicare patients
274
Services billed
1,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$41,144
VraylarCariprazine Hcl16$27,805
JanuviaSitagliptin Phosphate12$14,310
FarxigaDapagliflozin Propanediol15$12,787
MounjaroTirzepatide11$11,854
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$10,158
JardianceEmpagliflozin17$8,924
SymbicortBudesonide/Formoterol Fumarate15$2,981
Albuterol Sulfate HfaAlbuterol Sulfate129$2,561
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$1,920
Novolog FlexpenInsulin Aspart14$1,608
Pregabalin59$1,530
Pantoprazole Sodium149$1,461
Levothyroxine Sodium135$1,364
Metoprolol Succinate98$1,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$212$41,14456 claims
AbbVieVraylar$482$27,80516 claims
AstraZenecaFarxiga, Symbicort$123$15,76830 claims
Lilly USA, LLCMounjaro$224$11,85411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Weirton

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →